Since PARP trapping has been known to related with myelosuppression, which results in cytopenia such as anemia, thrombocytopenia, and neutropenia [29], veliparib is considered as a more suitable PARP inhibitor than other PARPi in combination with platinum-based chemotherapy. The gene discussed is PARP1; the disease is neutropenia.